Tirzepatide use is associated with a lower risk for CPAP use, hospitalization, and mortality in adults with obesity, T2D, and OSA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results